{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:44:37Z","timestamp":1790261077944,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Australia has had a framework for legal medicinal cannabis since 2016, yet prior online surveys in 2016 and 2018 indicated that most consumers continued to use illicit medical cannabis products. Regulatory data indicate an increase in the\u00a0prescription of\u00a0medicinal cannabis since 2019, and this survey examines consumer experiences of prescribed and illicit medical cannabis (MC) use in Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional anonymous online survey was\u00a0administered September 2020 to January 2021. Recruitment via social media, professional and consumer forums, and medical practices. Participant eligibility:\u2009\u2265\u200918\u00a0years; used a cannabis product for self-identified medical reason(s) in the past year, and resident in Australia. Outcome measures included<jats:italic>c<\/jats:italic>onsumer characteristics, conditions treated, source and patterns of MC use, and perspectives on accessing MC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 1600 participants (mean age 46.4\u2009\u00b1\u200914.3\u00a0years, 53% male), 62.4% (<jats:italic>n<\/jats:italic>\u2009=\u2009999) reported using only illicit and 37.6% (<jats:italic>n<\/jats:italic>\u2009=\u2009601) used prescribed MC in the past year. MC was used on a median of 28 (IQR: 12, 28) of the past 28\u00a0days and cost $AUD 74\u2009\u00b1\u200972 weekly (median\u2009=\u2009$40, IQR: $7, $100). Prescribed participants were more likely to treat pain conditions than those using illicit MC (52% v 40%, OR\u2009=\u20091.7, 1.3\u20132.1) and less likely to treat sleep conditions (6% v 11%, OR\u2009=\u20090.5, 0.3\u20130.8), with mental health conditions also a common indication in both groups (26%, 31%). Prescribed MC was consumed predominately by oral routes (72%), whereas illicit MC was most commonly smoked (41%). Prescribed MC was \u2018mainly THC\u2019 (26%), \u2018equal THC\/CBD\u2019 (40%), \u2018mainly CBD\u2019 (31%) and \u2018uncertain\u2019 (3%), while 34% of those using illicit MC were \u2018uncertain\u2019 of the\u00a0cannabinoid profile. Cost and difficulties finding medical practitioners to prescribe remain significant barriers to accessing prescribed MC, and few (10.8%) described the existing model for accessing prescribed MC as \u2018straightforward or easy\u2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There has been a notable shift from illicit to prescribed MC by many consumers compared to prior surveys. Consumers using prescribed MC reported a range of advantages compared to illicit MC, including safer routes of administration, and greater certainty regarding access and composition of products.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12954-022-00666-w","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T10:03:01Z","timestamp":1659175381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)"],"prefix":"10.1186","volume":"19","author":[{"given":"Nicholas","family":"Lintzeris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llewellyn","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah V.","family":"Abelev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Suraev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon C.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain S.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"666_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.904291","volume":"10","author":"D Fortin","year":"2022","unstructured":"Fortin D, Marcellin F, Carrieri P, Mancini J, Barr\u00e9 T. Medical cannabis: toward a new policy and health model for an ancient medicine. Front Public Health. 2022;10: 904291. https:\/\/doi.org\/10.3389\/fpubh.2022.904291.","journal-title":"Front Public Health"},{"key":"666_CR2","unstructured":"Narcotic Drugs Amendment Act 2016, No.12, 2016 (Commonwealth of Australia). https:\/\/www.legislation.gov.au\/Details\/C2016A00012. Accessed 30 Nov 2021."},{"key":"666_CR3","unstructured":"Freshleaf Analytics. (2021) Australian medicinal cannabis market patient, product and pricing analysis. https:\/\/freshleafanalytics.com.au\/report-h2-2021\/. Accessed 30 Nov 2021."},{"key":"666_CR4","unstructured":"Therapeutic goods administration. Medicinal cannabis\u2014guidance documents. 2019 Apr 29. https:\/\/www.tga.gov.au\/\u00a0medicinal-cannabis-guidance-documents [Accessed 30 Nov 2021]."},{"issue":"5","key":"666_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2020.052","volume":"43","author":"JC Arnold","year":"2020","unstructured":"Arnold JC, Nation T, McGregor IS. Prescribing medicinal cannabis [published correction appears in Aust Prescr. 2020 Dec; 43(6): 225]. Aust Prescr. 2020;43(5):152\u20139. https:\/\/doi.org\/10.18773\/austprescr.2020.052.","journal-title":"Aust Prescr"},{"key":"666_CR6","unstructured":"National prescriber service medicinal cannabis: what you need to know. Information and resources for consumers and health professionals. https:\/\/www.nps.org.au\/professionals\/medicinal-cannabis-what-you-need-to-know. Accessed 30 Nov 2021."},{"issue":"10","key":"666_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.31128\/AJGP-04-21-5939","volume":"50","author":"LA Henderson","year":"2021","unstructured":"Henderson LA, Kotsirilos V, Cairns EA, Ramachandran A, Peck CC, McGregor IS. Medicinal cannabis in the treatment of chronic pain. Aust J Gen Pract. 2021;50(10):724\u201332. https:\/\/doi.org\/10.31128\/AJGP-04-21-5939.","journal-title":"Aust J Gen Pract"},{"key":"666_CR8","unstructured":"RACGP. Medicinal cannabis webinar series. https:\/\/www.racgp.org.au\/education\/professional-development\/online-learning\/webinars\/medicinal-cannabis. Accessed 30 Nov 2021."},{"key":"666_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.885655","volume":"13","author":"SL MacPhail","year":"2022","unstructured":"MacPhail SL, Bedoya-P\u00e9rez MA, Cohen R, Kotsirilos V, McGregor IS, Cairns EA. Medicinal cannabis prescribing in Australia: an analysis of trends over the first five years. Front Pharmacol. 2022;13: 885655. https:\/\/doi.org\/10.3389\/fphar.2022.885655.","journal-title":"Front Pharmacol"},{"key":"666_CR10","unstructured":"Australian Institute of Health and Welfare 2020. National drug strategy household survey 2019. Drug statistics series no. 32. PHE 270. Canberra AIHW. https:\/\/www.aihw.gov.au\/reports\/illicit-use-of-drugs\/national-drug-strategy-household-survey-2019\/contents\/summary. Accessed 30 Nov 2021."},{"key":"666_CR11","unstructured":"Therapeutics Drug Administration (2021) Medicinal cannabis special access scheme category B data. https:\/\/www.tga.gov.au\/medicinal-cannabis-special-access-scheme-category-b-data. Accessed 30 Nov 2021."},{"issue":"5","key":"666_CR12","first-page":"211","volume":"209","author":"N Lintzeris","year":"2018","unstructured":"Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJ. Medicinal cannabis in Australia, 2016: the cannabis as medicine survey (CAMS-16). Med J A. 2018;209(5):211\u20136.","journal-title":"Med J A"},{"issue":"1","key":"666_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12954-020-00377-0","volume":"17","author":"N Lintzeris","year":"2020","unstructured":"Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, Benson MJ, McGregor IS. Medical cannabis use in the Australian community following introduction of legal access: the 2018\u20132019 online cross-sectional cannabis as medicine survey (CAMS-18). Harm Reduct J. 2020;17(1):37. https:\/\/doi.org\/10.1186\/s12954-020-00377-0.","journal-title":"Harm Reduct J"},{"issue":"1","key":"666_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manip Physiol Ther. 2004;27(1):26\u201335.","journal-title":"J Manip Physiol Ther"},{"issue":"2","key":"666_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"666_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"666_CR17","unstructured":"R: A language and environment for statistical computing [computer program]. R foundation for statistical computing; 2016."},{"key":"666_CR18","doi-asserted-by":"crossref","unstructured":"Wickham H. Tidyverse: Easily install and load \u2019tidyverse\u2019 packages. R package version 1.2.1. 2017. https:\/\/CRAN.R-project.org\/package=tidyverse.","DOI":"10.32614\/CRAN.package.tidyverse"},{"key":"666_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-21706-2","volume-title":"Modern applied statistics with S","author":"WN Venables","year":"2002","unstructured":"Venables WN, Ripley BD. Modern applied statistics with S. New York: Springer; 2002."},{"key":"666_CR20","unstructured":"Christensen RHB. Ordinal\u2014regression models for ordinal data. R package version 12\u201310. 2019. https:\/\/CRAN.R-project.org\/package=ordinal."},{"key":"666_CR21","unstructured":"Lenth RV. Emmeans: estimated marginal means, aka least-squares means. R package version 1.5.3. 2020. https:\/\/CRAN.R-project.org\/package=emmeans."},{"key":"666_CR22","unstructured":"Australian Parliament House. (2020) Senate community affairs references committee: inquiry into current barriers to patient access to medicinal cannabis in Australia. Commonwealth of Australia. ISBN: 978\u20131\u201376093\u2013059\u20132. https:\/\/www.aph.gov.au\/Parliamentary_Business\/Committees\/Senate\/Community_Affairs\/Medicinalcannabis\/Report. Accessed 30 Nov 2021."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00666-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:31:09Z","timestamp":1727681469000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00666-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00666-w","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"1 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Sydney University Human Research ethics Committee (2018\/544). In order to begin the survey, participants were asked to read a linked Participant Information Statement and to tick a check box giving consent for their data to be used in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof Lintzeris reports grants from the Australian National Health and Medical Research Council (NHMRC) during the conduct of the study; and research grants from Camurus and Indivior for unrelated work. A\/Prof Arnold and\u00a0Prof McGregor report grants from NHMRC and grants from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study for projects unrelated to the submitted work; Dr McGregor has patents to WO2018107216A1, WO2017004674A1 and WO2011038451A1 issued and licensed. A\/Prof Arnold and Prof McGregor have patents to AU2017904438, AU2017904072 and AU2018901971 pending. No other authors report conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}